Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

UCB (UCBJF) recently presented new data from the RAPID-PsA study and RAPID-axSpA study on Cimzia. The data was presented at the European League Against Rheumatism (EULAR) Congress.

According to the recent findings, active psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA) patients treated with Cimzia showed improvements in pain, fatigue and health-related quality of life. Cimzia-treated PsA and axSpA patients have shown better workplace and household productivity, as well as more participation in social and daily activities as compared to those being administered placebo.

Similar observations were seen in ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA) patients treated with Cimzia.

Cimzia is currently approved for Crohn’s disease and rheumatoid arthritis. Cimzia sales increased 27% year over year in the first quarter of 2013.

In Feb 2013, UCB filed with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for two additional indications – PsA and axSpA. These regulatory filings were based on the phase III RAPID-PsA and RAPID-axSpA studies.

RAPID-PsA was a double-blind, placebo-controlled, phase III study which showed improvements in the signs and symptoms of PsA compared to placebo in adult patients with or without prior anti-TNF (tumor necrosis factor) exposure.

RAPID-axSpA was a randomized, double-blind, placebo-controlled, phase III study which showed that both dosing regimens of Cimzia reduced the signs and symptoms of axSpA as compared to placebo.

Currently, the psoriatic arthritis market has drugs like AbbVie Inc.’s (ABBV - Analyst Report) Humira and Johnson & Johnson’s (JNJ - Analyst Report) Simponi among others.

UCB carries a Zacks Rank #3 (Hold). However, Santarus, Inc. looks more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%